trifermed, empresa amb seu a Barcelona especialitzada en estratègia corporativa i gestió de desenvolupament de negoci per a innovadors en salut, ha anunciat el seu trasllat al Pier07 de Tech Barcelona. Després de més de vint anys establerts a Sant Cugat del Vallès, el membre de CataloniaBio & HealthTech trasllada la seva seu a Pier07, el nou espai de salut i ciències de la vida de Tech Barcelona.

It has been led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound Bioventures, and existing investors Invivo Capital, AdBio Partners, and CDTI. Invivo Capital and AdBio Partners are both members of CataloniaBio & HealthTech, and the first ones participated in the creation of the company and were the first investors. Moreover, they have now played a leading role in attracting Series B investors.

Investment in Catalonia has a countercyclical behaviour in the startup ecosystem. While investments in Europe and the United States have registered significant decreases during 2022 in the amount of capital raised in the biotech and medtech sectors, the Catalan ecosystem continues to rise and has increased by 87% compared to the previous year, reaching a total of €445 million.

Perdigó, empresa de disseny i enginyeria de productes, equips i tecnologies mèdiques, i membre de CataloniaBio & Healthtech, ha presentat recentment Xaloc. Es tracta del disseny preliminar d’un inhalador de pols seca (IPS) de doble tira, que està disponible per al desenvolupament de productes combinats, tant genèrics com innovadors.

La companyia d’inversió personalitzada en biotecnologia i salut, membre de CataloniaBio & HealthTech, ha rebut l’autorització de la CNMV per operar sota la llei europea ECSP 2020/1503. Aquesta autorització permetrà a Capital Cell començar a operar de manera immediata a França, Alemanya, Itàlia, Portugal, Bèlgica i Dinamarca, a més d’obrir la possibilitat d’entrar a la resta de mercats de la Unió Europea amb més facilitat.

More than thirty CEOs from CataloniaBio & HealthTech met at the HUB cambraDigital (Barcelona Chamber of Commerce) on 19 April to discuss the situation of health as an economic sector. Following on from the reflections raised at the first CEO Council of the year, at the beginning of February with Antón Costas as guest speaker, in which a vision of health was raised not only from a social point of view but also as an element in the growth and prosperity of a society, proposing that health should begin to be seen in economics as an accounting element and not just as a cost.

Contera Pharma is a Danish biotech company developing innovativesmall-molecule and RNA-based therapeutics to address neurological disorders.Their unique R&D model integrates their team of experienced neurosciencedrug hunters with cutting-edge technology, like Abzu’s proprietary discovery engine, theQLattice®, to develop precision medicines.

ValueSprint TM has been a service focused on innovative companies or start-ups in the healthcare sector for more than two years at Idneo Medtech. This service provides a multidisciplinary team in engineering, design, regulatory aspects, manufacturing and even project management, with the aim of providing a series of initial answers to the typical questions that a company may have when trying to bring an ISO13485 certified medical product to the market.

The spin-off RetinaReadRisk has been created for marketing software and a mobile system based on artificial intelligence to detect diabetic retinopathy in the early stages. The founding partners are IISPV, UP2Smart (URV), Grupo TRC (Telefónica) and GENESIS Biomed, a CataloniaBio & HealthTech member. The creation of the company has been carried out within the framework of a project supported by EIT Health, an aspect that also gives it an international projection.

La Nit de CataloniaBio & HealthTech is the annual event of reference for the biomedicine and health sector in Catalonia, an institutional dinner-networking event that offers a unique opportunity to interact and talk with the main representatives of the sector.

CataloniaBio & HealthTech has presented the Bioèxit 2023 Award to SpliceBio and Avinent Implant System for the milestones achieved during 2022 in the field of health and life sciences in Catalonia. The award ceremony was held today as part of the CataloniaBio & HealthTech Gala at CaixaForum Barcelona, with more than 320 attendees, including authorities from international, state and Catalan public administrations, and members of the association among entrepreneurs, executives and investors in the sector.

BHV Partners, the first venture builder specialised in healthcare in Southern Europe, CataloniaBio & HealthTech member, has launched the start-up Conus Airway, which will focus on developing and marketing innovative medical devices that improve anaesthesia and surgery of the respiratory tract.

Foundation for Neglected Disease Research (FNDR) and DevsHealth, CataloniaBio & HealthTech member, have announced the start of a collaborative project to develop new broad-spectrum antiviral agents for infections caused by flaviviruses such as dengue, Zika, West Nile virus, and Japanese encephalitis, among others.

Laboratorios Gebro Pharma, S.A. and the startup HumanITcare have recently signed a collaboration agreement through which they will launch a connected health solution for patients with asthma. The relationship between the pharmaceutical company and the startup, which began in 2022 under the auspices of the Catalan Government’s Innovation Aid Programme for the Competitiveness of Enterprise (ACCIÓ), is now consolidated in a corporate-startup relationship.

The company, based in Barcelona and a CataloniaBio & HealthTech member, offers CRO (Contract Research Organization) services to main national and international pharmaceutical, biotechnological and medical device companies, is now celebrating its 25th anniversary.

ADmit Therapeutics, a CataloniaBio & HealthTech member, announces a new investment of up to $1,886,058 from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The investment represents a continuation of the Diagnostics Accelerator’s support for the clinical validation and regulatory approval of their breakthrough technology based on novel biomarkers related to mitochondrial DNA.

Asabys announces today the first investment of its new fund, SAHII II (Sabadell Asabys Healthcare Innovation Investments II), launched with the support of Banco Sabadell, in DeepUll, a Barcelona-based disruptive medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections. Both companies are CataloniaBio & HealthTech members.

Almirall, a global biopharmaceutical company focused on skin health, today announced anagreement with ZeClinics, a Contract Research Organization (CRO) specialized in zebrafish, to be based at Almirall's R&D centre. Both companies are CataloniaBio & HealthTech members. With this agreement, Almirall reinforces its aim to transform its R&D centre located in Sant Feliu de Llobregat into a uniquely collaborative environment where researchers from biotech companies, start-ups, academia, and other scientist meet with Almirall’s team to enhance research success.

AELIX Therapeutics S.L. (‘AELIX’), a clinical-stage biotechnology company, member of CataloniaBio & HealthTech, specialized in the discovery and development of immunotherapies for HIV infection, today announced positive topline results from the AELIX-003 trial.

Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.